Chiasma announces Raj Kannan to its Board of Directors as CEO alongside Mark Fitzpatrick as President

– USA, MA –  Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a management transition intended to further strengthen the Company’s leadership team ahead of the anticipated commercial availability of Mycapssa.

As part of the transition, the Company has appointed pharmaceutical commercial veteran Raj Kannan as Chief Executive Officer. Mr. Kannan will also join Chiasma’s Board of Directors.

The Company’s current Chief Executive Officer, Mark Fitzpatrick, will continue to serve as President. The management transition is expected to be effective no later than June 17, 2019.

Dave Stack, Chairman of the Board, said, “We are very pleased to welcome Raj to the Chiasma team at this critical time in the Company’s evolution. As we prepare to transition from a late-stage development company to a commercial-ready organization, we believe Raj has the ideal skill set to guide the Company through its next phase of growth. Raj brings a 25-year track record of global sales and marketing success at highly regarded commercial-stage pharmaceutical companies, and his leadership experience prepares him well to assume the role of Chief Executive Officer.

“We are also very fortunate to retain Mark Fitzpatrick as part of this transition in the role of President. Mark has been instrumental in shepherding the Company through the multinational clinical development of Mycapssa since he assumed the role of Chief Executive Officer in October 2016, and we expect to benefit from his deep institutional knowledge and continued leadership as we transition to a commercial-ready company. Mycapssa® represents a potential paradigm change in the maintenance treatment of adult patients with acromegaly, and with a world-class leadership team now in place, we look forward to potentially making this novel treatment available to patients worldwide,” Mr. Stack concluded.

Mr. Fitzpatrick said, “Raj joins Chiasma at a time when our planned transition into a commercial enterprise necessitates the vision and experience of a tried and true global commercial leader. I look forward to working with Raj and the rest of the Chiasma team as we plan for an expected mid-2020 PDUFA date for Mycapssa and develop our longer-term commercialization strategy in the E.U. and in other markets.”

About Raj Kannan

Prior to joining Chiasma, Mr. Kannan served as Chief Commercial Officer at Kiniksa Pharmaceuticals since July 2018. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in Multiple Sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and the resource allocation across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5B in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally.

Raj Kannan said, “I am very excited about the opportunity to lead Chiasma through the planned U.S. and global commercialization of Mycapssa®. What attracted me to the Company was the market potential for its first-in-class oral somatostatin analog, the quality, and stability of the team, and their perseverance to see this product candidate through to acromegaly patients whose needs are currently unmet by existing injectable treatments. I look forward to joining the team and building upon the Company’s mission.”

About Chiasma

Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In October 2018, the Company completed enrolment in CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated. Prior to trial initiation, the Company reached agreement with the FDA on the design of the trial through a Special Protocol Assessment. Chiasma is headquartered in Waltham, MA with a wholly-owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>